Curis | CRIS - Des Atouts





Des Atouts Changement Date
Alaunos Therapeutics USD 1.52M 367K 2026-06
Amgen USD 96.05B 409M 2026-09
AstraZeneca USD 119.92B 4.09B 2026-09
Bayer EUR 113.47B 6.18B 2026-09
Bristol-Myers Squibb USD 88.77B 1.14B 2026-09
CSL USD 37.9B 1.5B 2025-12
Curis USD 29.69M 9.72M 2026-03
Eli Lilly USD 148.07B 5.79B 2026-09
Exelixis USD 2.51B 19.26M 2026-09
Gilead Sciences USD 51.41B 2.05B 2026-09
GlaxoSmithKline GBP 71.7B 9.96B 2026-09
Incyte USD 7.29B 585.39M 2026-09
Merck USD 132.77B 2.97B 2026-09
Novartis USD 117.15B 4.88B 2026-09
Pfizer USD 204.54B 3.41B 2026-09
Roche Holding CHF 98.2B 2.5B 2026-06
Sanofi EUR 130.29B 1.23B 2026-09
Takeda JPY 15.27T 391.77B 2026-09
TG Therapeutics USD 1.64B 110.79M 2026-06
Verastem USD 227.81M 18.63M 2026-03